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Available online 11 March 2019Background:Myxoid liposarcoma (ML) exhibits a special sensitivity to trabectedin (T) and radiation therapy (RT).
Preclinical data suggest a synergistic effect.We aimed to study safety, feasibility and activity of the administration
of pre-operative concurrent T and RT in patients affected by localized resectable ML.
Methods: Patients received 3 cycles (C) of T in combinationwith RT (45 Gy) in 25 fractions (1.8 Gy/fraction). Dose
Levels for T were:−1 (1.1 mg/m2), 0 (1.3 mg/m2) and 1 (1.5 mg/m2). Primary endpoint was safety; antitumor
activity was assessed by RECIST and Choi criteria. This study is registered at ClinicalTrials.gov, number
NCT02275286. The phase 1 part of the study is complete and phase 2 is ongoing.
Findings: From February 2015 to May 2016, 14 patients (M/F 7/7), median age 36 years (range 24–70) and me-
dian tumor size 12.5 cm (range 7–17 cm), were enrolled. One dose limiting toxicity (G3 transaminitis) occurred
at Level 0 and one (sepsis due to catheter infection) at Level 1. All patients completed RT. Five patients achieved
PR (36%), 8 SD (57%), 1 distant PD (7%) by RECIST,while 12 achieved PR (86%), 1 SD (7%) and 1 distant PD (7%) by
Choi criteria. Twelve patients underwent surgery. Median viable residual tumor was 5% (0–60).
Interpretation: T in combination with RT showed a favorable safety proﬁle and antitumor activity in localizedML.
T dose of 1.5 mg/m2 is the recommended dose for the phase 2 study, which is ongoing.
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Myxoid liposarcoma (ML) is a rare soft tissue sarcoma (STS) subtype,
accounting for 30% of all Liposarcoma and 10% of all STS [1,2]. It arises
predominantly in the extremities of young adults and is characterized-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
We searched PubMed for published preclinical or clinical stud-
ies about the combination of trabectedin (T) and radiotherapy
(RT) in sarcomas from January 1997 to June 2018.Weused the fol-
lowing search terms: “sarcoma”, “soft tissue sarcoma”, “myxoid
liposarcoma”, “trabectedin”, “radiotherapy”, “neoadjuvant che-
motherapy”, “neoadjuvant radiotherapy”, “phase I study”, “phase
II study”. We identiﬁed only 2 preclinical studies suggesting a syn-
ergistic activity between the use of T and RT, based on the fact that
T typically causes S blockade and G2M arrest and the latter is the
most sensitive cell cycle phase to radiation treatment. There was
no single published clinical study testing the feasibility and activ-
ity of this combination in patients affected by soft tissue sarcoma
or localized myxoid liposarcoma.
Added value of this study
This is the ﬁrst-in-human clinical study showing the feasibility
of the concurrent administration of T and RT in patients affected
by localized myxoid liposarcoma. No cumulative toxicity was
shown and no treatment related deaths were recorded. The rec-
ommended T dose for the phase 2 study was 1.5 mg/m2, which
is the same dose registered for the use of T alone. In addition
85% of the patients had Choi partial response and 75% had b than
10% residual visible tumor in the surgical specimen. A conﬁrma-
tory phase 2 trial is ongoing.
Implications of all the available evidence
Neoadjuvant combined chemo-radiation therapy has been ex-
tensively explored in localized. STS. A recent randomized trial
showed a beneﬁt of neoadjuvant AI versus a histology-driven che-
motherapy in termsof OS andRFS, thus pointing to efﬁcacy of neo-
adjuvant treatment as such in a subset of STS. In the myxoid
liposarcoma stratum of this trial, the interim analysis showed
the non-inferiority of T, with a much better toxicity proﬁle. This
study is still recruiting in the myxoid liposarcoma stratum and is
expected to complete the accrual in a year. It is thus possible
that the efﬁcacy of T be conﬁrmed to be not inferior to that of AI.
The results of this phase I study provide the basis for the combina-
tion of T and RT for the phase II part, since no relevant toxicity was
observed and both radiological and pathologic assessments of re-
sponse indicate a synergy between bothmodalities. In the near fu-
ture T combined with radiation therapy may become a standard
neoadjuvant therapy for a subset of localized ML.
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ing FUS (also named as TLS) with CHOP (also named as DDIT3) and
rarely t(12;22)(q13;q12), where EWS (Ewing's Sarcoma protein)
substitutes for its homologous FUS [3]. The classic myxoid variant
shows low cellularity, conspicuous vascular network and myxoid
stroma, whereas the cellular variant shows high cellularity made
up of closely packed roundish cells, little or no intervening stroma
and a capillary pattern not easy to be visualized. Diagnosis of cellular
variant requires the presence of a cellular component exceeding 5%
[2,4]. This amount is of prognostic relevance as within the ML spec-
trum, the 5-year survival varies between 20 and 70% and the cellular
variant falls in the shortest ﬁgures.
Evidence of a signiﬁcant activity of both anthracycline and
trabectedin (T) as well as radiotherapy (RT) has been consistently re-
ported in patients affected by metastatic ML [5–7].Aphase II study on neoadjuvant T in 23 patients affected by localized
resectable ML showed a 24% response rate by RECIST and a 13% patho-
logical complete response in the surgical specimenwith a very favorable
toxicity proﬁle [8].
Some preclinical data of the synergistic activity of RT and T have
been reported [9] based on the fact that T typically causes S blockade
andG2/Marrest and it iswell known that this latter is themost sensitive
cell cycle phase to radiation treatment [10].
Aim of the present study was to test the safety, feasibility and activ-
ity of the administration of pre-operative T with concurrent RT in pa-
tients affected by localized resectable ML. This study included also a
separate group of metastatic STS patients, where the same was tested
to treat metastatic STS to the lung not suitable to surgical resection.
We present herein data from the phase 1 part of the study limited to
the cohort of localized ML patients. The phase 2 part of the study is
ongoing.
2. Methods
2.1. Study Design and Participants
This is an international, open label, phase 1 study aimed at testing
the safety and feasibility of the concurrent administration of T and RT
and ﬁnding the appropriate T dose to use in the phase 2 part of the
study. Patients were enrolled in 4 centres in Spain, 1 in Italy and 2 in
France.
Patients were eligible if they were aged between 18 and 70 years;
had a histologically proven and centrally reviewed (before inclusion)
diagnosis of localized resectable ML, originating in an extremity or
trunk wall, with a longest diameter ≥ 5 cm if deeply or 10 cm if superﬁ-
cially located relative to the investing fascia; had an Eastern Cooperative
Oncology Group performance status equal or less than 1; had adequate
baseline bone marrow (white blood cell count N3000 cells per μL, neu-
trophil N1500 cells per μL, platelets N100,000 platelets per μL, and
haemoglobin N10 g/L), renal function (creatinine b1·6 mg/dL), hepatic
function (total bilirubin ≤ upper normal value [UNV], transaminase and
phosphatase alkaline ≤2·5 the UNV), creatine phoshokinase (≤2·5 the
UNV) and cardiac function (left ventricular ejection fraction N50%).
Patients were ineligible if they had unresectable disease with limb
sparing surgery or distant metastases; had disease located outside the
extremities or trunk wall; had other malignancies within the past
5 years, with the exception of carcinoma in situ of cervix and
basocellular skin cancers treated with eradicating intent; had previous
T or RT involving the tumor bed; had serious psychiatric disease; had
medical disease limiting survival to less than 2 years; had cardiovascular
diseases resulting in aNewYorkHeart Association Functional Status of 2
or higher; or had uncontrolled bacterial, viral, or fungal infection. Other
inclusion and exclusion criteria can be found in the appendix.
The trial protocol and all amendments were approved by the appro-
priate institutional review board or independent ethics committee at
each trial centre. The trial was done in accordance with the provisions
of the Declaration of Helsinki. All patients provided written informed
consent before enrolment. The full protocol is available in the appendix.
2.2. Procedures
The dose escalation rules proceeded according to the traditional 3
+ 3 design [11] being the prespeciﬁed dose-limiting toxicity (DLT) as
follows: neutrophil count b0.5 × 109/L during ≥5 days, febrile neutrope-
nia, platelet count b50×109/L andnon-haematological toxicity of grade
3 or above, excluding nausea/vomiting without appropriate antiemetic
treatment and grade 3 transaminitis if not leading to T delay. Biochem-
istry and full blood count was performed on day 1 and weekly, in the
two ﬁrst cycles at least. Patients received 3 cycles of T in combination
with RT (total dose of 45 Gy) in 25 fractions (1.8 Gy/fraction). For
those patients with micro or macroscopic positive margins after
Fig. 1. Outline of the trial design.
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fraction) was allowed (Fig. 1).
T was administered intravenously as a 24 h infusion every 3 weeks.
The planned dose-levels for T were as follows: −1 (1.1 mg/m2), 0
(1.3mg/m2) and 1 (1.5mg/m2). Oral dexamethasone 4mgwas admin-
istered 24 h and 12 h before chemotherapy administration and i.v.
dexametasone 20mgwas given 30 min before treatment, as previously
described to minimize toxicity [12]. Administration of T through a cen-
tral venous catheter was mandatory, due to ﬁbrotic phlebitis encoun-
tered during peripheral administration. The starting dose-level for T,
1.3 mg/m2 was chosen based on previous accumulated experience,
since this dose had shownactivity in the context ofmyxoid liposarcoma.
RT started within 1 h after completion of the ﬁrst T infusion (cycle
1 day 2), and was given daily for 25 days. Patients were treated with
3D conformal radiotherapy (3D-CRT) or intensity modulated radiother-
apy (IMRT). Gross tumor volume (GTV) included gross tumor deﬁned in
the planning CT or contrast enhancedMRI T1 images. Clinical target vol-
ume (CTV) included GTV plus longitudinal margins (proximal and dis-
tal) of 5 cm and a radial margin of 2 cm. If after applying these
margins the ﬁeld extended beyond an intact fascia, the ﬁeld could be
shortened to include the entire compartment. Planning target volume
(PTV) included the CTV plus an additional margin to compensate for
organ motion and set-up uncertainties. Typically, this was CTV + 0
.5cm.
In the interval period, the tests were repeated at the discretion of the
treating physician.We graded toxic effects using theNational Cancer In-
stitute Common Terminology Criteria for Adverse Events version 4.03.
Acute Tmediated cardiac toxicitywas not expected at protocol spec-
iﬁed dose. However, an intermediate LVEF evaluation was mandatory
within 2 weeks after last day of RT treatment with the same method
as in the initial evaluation. If a decrease N15% was observed the patient
was to bewithdrawn from the study. If a patient experienced a grade N1
toxicity and did not recover to grade ≤1 after a maximum 3-weeks
delay, the patient was to be withdrawn from the study.
Cardiac toxicities grade ≥ 4 were considered SUSAR (suspected un-
expected serious adverse reaction) and should have been reported in
less than 24 h.
We assessed response according to Response Evaluation Criteria in
Solid Tumours (RECIST) 1.1 [13] and Choi criteria [14] at the time of sur-
gery with contrast-enhanced MRI or CT scan, or both, in all patients. A
central radiological review of responses was performed in all cases at
the Fondazione IRCCS Istituto Nazionale dei Tumori – Milan – Italy.
Surgery was planned 3–4 weeks after the administration of last pre-
operative cycle and not until 4 weeks after the end of preoperative RT.
Following the resection, pathologic specimens were mapped in tumor
sections to estimate the histologic changes and viable tumor after neo-
adjuvant treatment.
We followed up patients every 4 months with chest and abdominal
CT and MRI or CT of the affected site.2.3. Outcomes
Aim of the study was to conﬁrm that the combination of T plus RT
is feasible and safe and shows potential synergic activity with low
toxicity.The primary end-pointwas to describe the safety proﬁle of the com-
bination of T plus RT in order to ﬁnd the recommended T dose for the
phase II part of the study.
Secondary end-points were radiological response, measured by
RECIST 1.1 and Choi criteria, and pathological response; recur-
rence free survival (RFS), disease free survival (DFS) and overall
survival (OS); quality of Life measured by QLQ-C30 EORTC
questionnaire.
2.4. Statistical Analysis
Wedid a 3+3 dose escalationwith reviewof available safety before
initiating the next dose level. Sample size for dose escalation was based
on the 3+ 3 design rules with three to six patients per dose level. Three
patients were treated at a given dose level. If at least 2 patients were ob-
served to have dose-limiting toxicity (DLT), the prior dose level was de-
ﬁned as the maximum tolerable dosage (MTD) (unless only 3 patients
have been treated at that level, in which case it is the tentative MTD).
If 0 of the 3 patients were observed to have DLT, the dose level was es-
calated one step for the next cohort of 3 patients, and the process con-
tinued as above. If exactly 1 of the 3 patients treated showed DLT, 3
additional patients were treated at the current dose level. If none of
these additional 3 patients showed DLT, the dose level was escalated
for the next cohort of 3 patients, and the process continues as above;
otherwise, the prior dose level was deﬁned as the MTD.
The dose-escalation levels were: −1: Trabectedin 1.1 mg/m2; 0:
Trabectedin 1.3 mg/m2 and 1: Trabectedin 1.5 mg/m2. The starting
dose-level was 1.3 mg/m2 and it was designed a de-escalation dose
(−1) of 1.1 mg/m2 in the case of observing more than one DLT over 6
patients in the starting dose, and one escalation dose (1) at
1.5 mg/m2, the ceiling dose recommended for trabectedin, in case of
ﬁnding ≤1 DLT in the starting dose. It was not allowed de-escalating
or escalating the dose on an individual basis, beside the deﬁned dose re-
ductions according to the protocol.
Dose reductions were done taking into account the highest tox-
icity in the prior cycle. Only two dose reductions were allowed in
the same patient, except in cases of evident clinical beneﬁt for
the patient however, discussion with and approval by the steering
committee (SC) and the Sponsor were mandatory. Once a dose re-
duction had taken place, re-escalation was not permitted in subse-
quent cycles. Every dose-reduction would imply decrease the dose
in 0.2 mg/m2.
Haematological toxicity: With any of the following toxicities re-
duced one dose level:
• Neutropenia b0,5 × 109/l, for more than 5 days
• Febrile neutropenia
• Thrombocytopenia b25 × 109/l
Non-haematological toxicity:With any of the following toxicities re-
duced one dose level:
• Vomiting ≥ grade 3 in spite of adequate treatment
• Transaminases elevation ≥ grade 3, not recovering to grade 1 previous
to T administration.
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during treatment.
• Other toxicities ≥ grade 3.
Safety and efﬁcacy analyses were done on all patients receiving at
least one cycle of trabectedin.
Treatment related adverse events (AEs) were those reported as pos-
sibly or probably related to treatment by the treating physician. Analysis
AEs included any unfavorable and unintended sign (including abnormal
laboratory ﬁndings), symptom or disease temporally associated with T
and/or RT.
Time to event variables (RFS, DFS and OS) were measured from the
date of surgery for RFS, and from onset of trial therapy for DFS and OS
and were estimated according to the Kaplan–Meier method.
This study is registered with ClinicalTrials.gov, number
NCT02275286
2.5. Role of the Funding Source
The TRASTS trial was an international academic trial designed by the
members of the steering committee of the trial whowere appointed by
the National Cooperative Sarcoma groups. No pharmaceutical company
had any role in study design, data collection, data analysis, data inter-
pretation, or writing of the report. PharmaMar provided the study
drug T and a small support for data management. Data were collected
by investigators and associated site personnel, analyzed by statisticians
working in the independent trial centre of the Spanish Sarcoma Group
(GEIS), and interpreted by the members of the steering committee.
The corresponding author had ﬁnal responsibility for the decision to
submit for publication.
3. Results
From February 2015 to May 2016, 14 patients (M/F 7/7) with me-
dian age of 36-years (range 24–70) and median tumor size of 12.5 cmTable 1
Patients and treatment characteristics.
Global series (n = 14)
Median age (range) 36 (24–71)
Sex (M/F) 7 (50%)/7 (50%)
ECOG PS
- 0
- 1
9 (62%)
5 (38%)
Grade
- 1
- 3
11 (79%)
3 (21%)
Location
- Thigh
- Leg
- Buttock
10 (71%)
3 (21%)
1 (7%)
Median size mm. (range) 130 (70–200)
Depth
- Deep
- Superﬁcial
14 (100%)
0
Radiotherapy dose
- 45 G
- 50 Gy
13 (93%)
1 (7%)
Surgery
- Yes
- No (n = 2)
12 (86%)
2 (14%)a
Surgical margin
- Free
- Positive
7 (58%)
5 (42%)
CHOP rearrangement
- Positive
- Not available
12 (86%)
2 (14%)b
a 2 patients did not undergo surgery, one because developedmetastatic disease during neoad
and was treated by deﬁnitive RT.
b 2 not evaluable for limited material on the biopsy and lack of residual tumor on the surgic(range 7–20 cm)were enrolled. Clinical and pathological characteristics
of the study cohort are listed in Table 1.
7 patients received T at dose Level 0 and 7 patients at Level 1. All pa-
tients completed the 3 planned cycles of T, but one who had a sepsis
after cycle 1 and received deﬁnitive RT. The median total dose of T
was 2.6 mg per cycle in both cohorts (range 2.11–2.85 in dose level 0
and 2.4–3.2 in dose level 1). Seven patients were allowed to be enrolled
in each dose-level, instead of the prespeciﬁed six, because one patient
had an early treatment discontinuance, and another did not undergo
surgery. Even though DLT analysis was based on ﬁrst cycle, it was con-
sidered that at least 6 patients had to complete the whole treatment
program for a better safety assessment. No dose reductions were ob-
served in the enrolled patients. Therewere no treatment related deaths.
All underwent RT to a median total dose of 45 Gy (range 45–50 Gy).
One DLT (G3 transaminitis) occurred at Level 0 and another (sepsis due
to catheter infection) at Level 1. Overall the combination of T and RTwas
well tolerated. Regardless of the dose attribution the most common
grade 3/4 AE was ALT elevation (n = 6, 43%). In addition gammaGT el-
evation, neutropenia, anemia, epithelitis and sepsis were observed in 1
patient each (7%). Other common grade 1/2 AEs were nausea (n = 7,
50%) and vomiting (n = 3, 21%), fatigue (n = 6, 43%) and anorexia
(n = 3, 21%), skin disorders (n = 4, 28%) and AST (n = 6, 43%) and
gammaGT (n = 3, 21%) elevation. The complete list of side effects
and grade is shown in Table 2, overall and by dose level. Conﬁdence
interval for the major toxicities is reported in Table 3.
All patients were evaluable for centralized assessment of response
by RECIST and Choi criteria: 5 achieved PR (36%), 8 SD (57%), 1 distant
PD (7%) by RECIST, while 12 achieved PR (86%), 1 SD (7%) and 1 distant
PD (7%) by Choi criteria (Fig. 2).
12/14 patients underwent surgery. All had a macroscopic complete
resection.Microscopic surgicalmarginswere negative (R0) in 7 patients
and positive (R1) in 5. Two patients were not operated, one because de-
veloped metastatic disease during neoadjuvant therapy and one be-
cause developed a sepsis due to central venous catheter infection and
was treated by deﬁnitive RT.1.3 mg/m2 dose (n = 7) 1.5 mg/m2 dose (n = 7)
31 (24–71) 53 (28–68)
4 (57%)/3 (43%) 3 (43%)/4 (57%)
5 (71%)
2 (29%)
4 (57%)
3 (43%)
7 (100%)
0 (0%)
4 (57%)
3 (43%)
6 (86%)
0 (0%)
1 (14%)
4 (57%)
3 (43%)
0
130 (30–170) 110 (57–200)
7 (100%)
0
7 (100%)
0
7 (100%)
0
6 (86%)
1 (14%)
6 (86%)
1 (14%)
6 (86%)
1 (14%)
4 (67%)
2 (33%)
3 (50%)
3 (50%)
6 (86%)
1 (14%)
6 (86%)
1 (14%)
juvant therapy and onebecause developed a sepsis due to central venous catheter infection
al specimen.
Table 2
Haematological and non-haematological toxicity.
Any grade Grade 3–4 Grade 1–2
Type of adverse event (n = 14) Any grade
N (%)
Dose level 0
(1.3 mg/m2)
Dose level 1
(1.5 mg/m2)
Grade 3–4
N (%)
Dose level 0
(1.3 mg/m2)
Dose level 1
(1.5 mg/m2)
Grade 1–2
N (%)
Dose level 0
(1.3 mg/m2)
Dose level 1
(1.5 mg/m2)
Haematological
Anemia 11 (78.5) 6 (42.8) 5 (35.7) 1 (7.1) 1 (7.1) 0 (0) 10 (71.4) 5 (35.7) 5 (35.7)
Neutropenia 8 (57.1) 2 (14.3) 6 (42.8) 2 (14.3) 0 (0) 2 (14.3) 6 (42.8) 2 (14.3) 4 (28.5)
Lymphopenia 8 (57.1) 4 (28.5) 4 (28.5) 1 (7.1) 1 (7.1) 0 (0) 7 (50.0) 3 (21.4) 4 (28.5)
Leukopenia 6 (42.8) 1 (7.1) 5 (35.7) 0 (0) 0 (0) 0 (0) 6 (42.8) 1 (7.1) 5 (35.7)
Thrombocytopenia 3 (21.4) 1 (7.1) 2 (14.3) 0 (0) 0 (0) 0 (0) 3 (21) 1 (7.1) 2 (14.3)
Non-haematological
ALT/GPT increased 12 (85.7) 7 (50.0) 5 (35.7) 7 (50) 6 (42.8) 1 (7.1) 5 (35.7) 1 (7.1) 4 (28.5)
AST/GOT increased 12 (85.7) 7 (50.0) 5 (35.7) 0 (0) 0 (0) 0 (0) 12 (85.7) 7 (50.0) 5 (35.7)
Nausea 7 (50.0) 4 (28.5) 3 (21.4) 0 (0) 0 (0) 0 (0) 7(50.0) 4 (28.5) 3 (21.4)
Fatigue 6 (42.8) 3 (21.4) 3 (21.4) 0 (0) 0 (0) 0 (0) 6 (42.8) 3 (21.4) 3 (21.4)
Skin disorders (dermatitis, epitelitis, erythema) 5 (35.7) 2 (14.3) 3 (21.4) 1 (7.1) 1 (7.1) 0 (0) 4 (28.5) 1 (7.1) 3 (21.4)
GGT increased 10 (71.4) 6 (42.8) 4 (28.5) 1 (7.1) 1 (7.1) 0 (0) 9 (64.2) 5 (35.7) 4 (28.5)
Anorexia 4 (28.5) 2 (14.3) 2 (14.3) 0 (0) 0 (0) 0 (0) 4 (28.5) 2 (14.3) 2 (14.3)
CPK increased 4 (28.5) 2 (14.3) 2 (14.3) 0 (0) 0 (0) 0 (0) 4 (28.5) 2 (14.3) 2 (14.3)
Vomiting 3 (21.4) 1 (7.1) 2 (14.3) 0 (0) 0 (0) 0 (0) 3 (21.4) 1 (7.1) 2 (14.3)
Diarrhea 2 (14.3) 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 2 (14.3) 1 (7.1) 1 (7.1)
Dyspepsia 2 (14.3) 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 2 (14.3) 1 (7.1) 1 (7.1)
Epigastralgia 2 (14.3) 2 (14.3) 0 (0) 0 (0) 0 (0) 0 (0) 2 (14.3) 2 (14.3) 0 (0)
Alkaline phosphatase increased 2 (14.3) 0 (0) 2 (14.3) 0 (0) 0 (0) 0 (0) 2 (14.3) 0 (0) 2 (14.3)
Sepsis 1 (7.1) 0 (0) 1 (7.1) 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 0 (0)
Catheter related infection 1 (7.1) 0 (0) 1 (7.1) 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 0 (0)
Abdominal pain 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 0 (0) 1 (7.1) 0 (0) 1 (7.1)
Dizziness 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 (7.1) 0 (0)
Headache 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 0 (0) 1 (7.1) 0 (0) 1 (7.1)
Myalgia 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 (7.1) 0 (0)
Haemoglobinuria 1 (7.1) 0 (0) 1 (7.1) 0 (0) 0 (0) 0 (0) 1 (7.1) 0 (0) 1 (7.1)
Limb cramps 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 (7.1) 0 (0)
Hypersialorrea 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 (7.1) 0 (0)
Venous injury 1 (7.1) 1 (7.1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (7.1) 1 (7.1) 0 (0)
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(0–60) with 9/12 patients (75%) with ≤10% visible remaining tumor.
Three of them (3/12, 25%) had a complete pathological response, with
no visible residual tumor (Fig. 3).
Median follow-up from surgery was 26 months (range 24–41). One
patient developed local and distant progression at the end of the neoad-
juvant treatment and one patient developed distant metastases
15months after surgery. This latter recurred in the central nervous sys-
tem and ﬁnally died 5 months later. This case was the only registered
death of this series.
The corresponding RFS, DFS and OS at 3-yr were 92% (95%CI:
76–100), 86% (95%CI: 67–100) and 93% (95%CI: 79–100), respectively
(Fig. 4).Table 3
Overall 95% Conﬁdence Interval of the major toxicities.
Type of adverse event (n = 14) Any grade
N (%; 95%CI)
Haematological
Anemia 11 (78; 54–100
Neutropenia 8 (57; 27–87)
Lymphopenia 8 (57; 27–87)
Leukopenia 6 (43; 13–72)
Thrombocytopenia 3 (21; 0–46)
Non-haematological
ALT/GPT increased 12 (86; 65–100
AST/GOT increased 12 (86; 65–100
Nausea 7 (50; 20–80)
Fatigue 6 (43; 13–72)
Skin disorders (dermatitis, epitelitis, erythema) 5 (36; 7–64)
GGT increased 10 (71; 44–98)
Anorexia 4 (28; 1–56)
CPK increased 4 (29; 1–56)4. Discussion
In this phase 1 study in patients affected by localizedML, the neoad-
juvant administration of concurrent T and RTwaswell tolerated. No cu-
mulative toxicity was shown and no treatment-related deaths were
observed. The recommended T dose for the phase 2 study was
1.5 mg/m2, which is the same dose approved for T alone. In addition,
both radiological and pathological responses were promising. A conﬁr-
matory phase 2 trial is ongoing.
This is the ﬁrst-in-human study of the combination of T and RT. Both
T and RT are known to have exceeding activity in patients affected by
ML. However, while preclinical data about the concurrent administra-
tion of the two modalities are available, no clinical studies had beenGrade 3–4
N (%; 95%CI)
Grade 1–2
N (%; 95%CI)
) 1 (7; 0–23) 10 (71; 44–98)
2 (14; 0–35) 6 (43; 13–72)
1 (7; 0–23) 7 (50; 20–80)
0 (0) 6 (43; 13–72)
0 (0) 3 (21; 0–46)
) 7 (50; 20–80) 5 (36; 7–64)
) 0 12 (86; 65–100)
0 7(50; 20–80)
0 6 (43; 13–72)
1 (7; 0–23) 4 (29; 1–56)
1 (7; 0–23) 9 (64; 36–93)
0 4 (28; 1–56)
0 4 (29; 1–56)
Fig. 2.Waterfall plot of radiological responses after treatment by Choi criteria, including both tumor size and density information. *Patient with progressive disease due to new distant
lesions while achieving CHOI partial response on primary tumor.
40 A. Gronchi et al. / EClinicalMedicine 9 (2019) 35–43performed so far. Of note the dose of RT was slightly lower (45 Gy) than
the one conventionally used in sarcomas in the preoperative setting
(50 Gy). A study speciﬁcally addressing to which extent the dose of RT
can be reduced in MLwithout compromising activity is presently ongo-
ing (DOREMY trial, NCT02106312). The next question to answer may
well be if the addition of T can be of any help also in this perspective.
The use of preoperative chemo-radiotherapy is increasingly
employed in localized high-risk STS of the extremities and trunk wall,
as it theoretically allows covering both the local and systemic risks
[15–20], while helping maximize local control in a proportion of chal-
lenging cases. This is of particular relevancewhen function preservation
is a goal, or the tumor is of borderline resectability and subsequent re-
currences may directly lead to death [21]. Indeed, the preoperative de-
livery of anthracycline + ifosfamide (AI) and RT was proven to be
feasible in an Italian and Spanish Sarcoma Group phase 3 randomized
study comparing the use of 3 and 5 cycles of AI [22]. Other single-armFig. 3. Panel a and d are examples of non-treated low grade and high grademyxoid liposarcoma
observed after the combination of trabectedin and radiotherapy: mature adipocytic different
inﬂammatory inﬁltrate, vascular reactive proliferation and haemosideraphages (panel f). All chstudies are available [23–25]. However this combination was consis-
tently shown to be more toxic as compared to the administration of AI
alone. A marked thrombocitopenia in as many as 35% of the patients
along with the other expected haematological toxicities was observed.
Nonetheless the dose intensity of AIwasmaintained. Of note the admin-
istration of the 2 treatments together proved to offset thenegative prog-
nostic impact of planned positive surgical margins on outcome [26,27].
As far as the efﬁcacy of neoadjuvant chemotherapy on the systemic
risk is concerned, at an interim analysis, another randomized study [28]
comparing neoadjuvant AI versus a neoadjuvant histology-driven che-
motherapy showed a statistically signiﬁcant beneﬁt in RFS and OS in
favor of AI, thus pointing to a distinct effect of neoadjuvant chemother-
apy as such in localized STS. If the ﬁnal analysis conﬁrms these results,
neoadjuvant chemotherapymay become standard treatment in a subset
of localized STS patients. However, in the same trial, T was the
histology-driven chemotherapy for ML, and at the moment it is therespectively. Panels b, c, e and f are examples of different patterns of pathological response
iation (panel b), necrosis (panel c), sclero-hyalinosis (panel e) and areas of ﬁbrosis with
anges can coexist in the same case.
Fig. 4. Relapse-free survival of the 12 operated patients (panel A); disease-free survival (panel B) and overall survival (panel C) of the 14 included patients.
41A. Gronchi et al. / EClinicalMedicine 9 (2019) 35–43only stratum in which the two arms were superimposable with regard
to RFS and OS. T had a much better toxicity proﬁle. This study is still
recruiting in the ML stratum and is expected to complete the accrual
in a year. It is thus possible that the efﬁcacy of T be conﬁrmed to be
not inferior to that of AI.
If so, in the near future T combined with radiation therapy may be-
come a standard neoadjuvant therapy for a subset of localized ML. For
the moment, this Phase 1 study actually showed the feasibility of the
combination of T with pre-operative radiation therapy.
Other studies have explored so far the combination of RT with che-
motherapy in localized STS. A phase 1 study on preoperative continuous
infusion Adriamycine over 5 days for 5 courses and concurrent RT to a
total dose of 50 Gy was performed on 27 patients affected by localized
high risk STS of an extremity or trunk wall. The treatment was fairly
well tolerated, but 30% of the patients developed a ≥ 3 skin toxicity,
along with the expected haematological side effects [29]. This regimen
has not been further developed,mainly due to the observed skin toxicity
and the use of a single agent regimen, which is not the standard chemo-
therapy approach used in localized high risk STS when a decision for an
adjuvant/neoadjuvant chemotherapy is taken. More recently a phase 1
study on Gemcitabine administered 5 times and concurrent RT to a
total dose of 50 Gy was performed. The treatment was well tolerated.
No signiﬁcant ≥3 skin toxicity was observed. The main side effect was
myelosuppression, which did not prevent the patients to complete the
preoperative treatment [30]. A formal phase 2 study to assess the activ-
ity of this regimen was warranted, but no results are available as of yet.
However Gemcitabine is not active in ML and therefore its use in com-
bination with RT in this disease would not be the ﬁrst choice.With regard to the combination of RT with targeted therapies, the
combination of Vascular Endothelial Growth Factor Receptor (VEGFR)
inhibitors and RT has also been studied in the latter years [31–33]. Suni-
tinib, Pazopanib or Sorafenib and combined RT to a total dose of 50 Gy
have been tested in phase I studies, in patients affected by high risk
STS in an extremity or trunkwall. The combination has proven to be fea-
sible. However grade ≥ 3 haematological and hepatic toxicities were ob-
served in up to 50% of the patients. In addition the effect of VEGFR
inhibitors against the metastatic risk of localized high risk STS is far
from being demonstrated and a limited activity in advanced
liposarcoma has consistently been reported for all these compounds.
Their use is mainly intended at enhancing RT activity. A conﬁrmatory
phase II study on the combination of Pazopanib and RT is presently
ongoing.
Another approach explored the combination of intratumoral injec-
tion of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and
RT in a phase 1 study in 22 patients affected by STS in an extremity or
trunk wall [34]. The treatment proved to be feasible, with limited local
toxicity. A promising pathological response rate was observed. A conﬁr-
matory phase 3 study has recently been completed. However this mo-
dality is not intended to impact the metastatic and survival risk as the
activity of both modalities is limited to the site of the primary tumor.
As a matter of fact, in the 14 patients of this Phase 1 component of
the trial, an impressive activity of the combination of T with RT was ob-
served, especially when radiological response was measured by modi-
ﬁed Choi criteria [14,35] (Fig. 2), known to better predict both
pathological response and ﬁnal outcome. Indeed the 75% rate of very
good pathological response (≤10% residual visible tumor) looks very
42 A. Gronchi et al. / EClinicalMedicine 9 (2019) 35–43promising. These results compare favorably with previous experiences
using either T or RT alone as neoadjuvant therapies in localized ML [7,
8]. However, if the phase II part of this study conﬁrmed the promising
activity reported herein, a comparative trial would be needed to dem-
onstrate the superiority of T plus RT over either single therapeutic mo-
dality in localized ML.
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